[Bioinformatician]

Treatments to life-threatening diseases already exists but they are not personalized, not customized to a person and his or her (meta/epi)genome, lifestyle, etc. This should change in the next 5 years with moire omics in the clinic and drug research. The best solution is not to need treatment for many diseases because people have figured out how to stay healthy.

• This reply was modified 5 years ago by Bioinformatician.

[Bioinformatician]

@jasonblu: I wonder what you meant by “Based on what I read, these types of test pull from prominent genes. This means as the percentages get smaller, there is more likely to be room for error” What do you call a prominent gene? Which percentages?

[Bioinformatician]

Epigenetic markers are not yet currently measured in the clinic but it involves detecting methylation of DNA. The breast cancer genes’ promoter methylation of seven genes were evaluated in a recent study (APC, BRCA1, CCND2, FOXA1, PSAT1, RASSF1A and SCGB3A1) by measuring Methylation levels in primary BrC tissues by quantitative methylation-specific polymerase chain reaction (QMSP) and in circulating cell-free DNA (ccfDNA) by multiplex QMSP
The gene-panel APC, FOXA1, RASSF1A, SCGB3A1 discriminated normal from cancerous tissue with high accuracy (95.55%) high PSAT1-methylation levels [>percentile 75 (P75)] were associated with longer disease-free survival, whereas higher FOXA1-methylation levels (>P75) associated with shorter disease-specific survival.

The study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262630/

[Author]

Posts